220962 Asymptomatic Hyperuricemia and the Risk of New-Onset Chronic Kidney Disease in Japanese Males over 40 Years of Age: A Long-term Retrospective Cohort Study

Sunday, November 7, 2010

Masatoshi Kawashima , Department of Preventive Medicine and Public Health, Kitasato University School of Medicine, Japan, Sagamihara, Japan
Koji Wada , Department of Preventive Medicine and Public Health, Kitasato University School of Medicine, Japan, Sagamihara, Japan
The aim of this study was to determine the associations of new-onset chronic kidney disease (CKD) with asymptomatic hyperuricemia, low serum high-density lipoprotein cholesterol (HDL-C), hypertension, diabetes, and obesity. Participants were all males over 40 years of age from 1990 to 2007 in a factory in Kanagawa Prefecture, Japan. This study was excluded participants who had a history of gouty attacks. By following the estimated glomerular filtration rate (eGFR), we conducted a retrospective cohort study with 1,285 participants. The endpoint was new-onset CKD defined as eGFR less than 60 ml/min/1.73 m2. The average („b standard deviation) follow-up period was 95.2 („b 66.7) months. During the follow-up period, 100 participants (7.8%) developed CKD. Cox proportional hazards model revealed that the hazard ratio of new-onset CKD was 3.99 (95% confidence interval [CI]: 2.59-6.15) among participants with hyperuricemia. For participants with low serum HDL-C and hypertension, the hazard ratios were 1.69 (95% CI: 1.00-2.86) and 2.00 (95% CI: 1.29-3.11), respectively. This study suggested that the magnitude of association between asymptomatic hyperuricemia and new-onset CKD was higher than established predictors such as hypertension and diabetes.

Learning Areas:
Chronic disease management and prevention
Epidemiology
Occupational health and safety

Learning Objectives:
Asymptomatic hyperuricemia is demonstrated for a predictor of chronic kidney disease.

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: I am qualified to present because I oversee all steps in this study such as case sampling and analyzing.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.